Search

Your search keyword '"David R Lynch"' showing total 96 results

Search Constraints

Start Over You searched for: Author "David R Lynch" Remove constraint Author: "David R Lynch"
96 results on '"David R Lynch"'

Search Results

1. The current state of biomarker research for Friedreich’s ataxia: a report from the 2018 FARA biomarker meeting

2. Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy.

3. Somatic instability of the expanded GAA repeats in Friedreich's ataxia.

4. Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia.

7. Efficacy of Omaveloxolone in Friedreich's Ataxia: <scp>Delayed‐Start</scp> Analysis of the <scp>MOXIe</scp> Extension

8. Patient-Reported Impact of Symptoms in Friedreich Ataxia

9. Friedreich ataxia: clinical features and new developments

11. Plasma multi-omics analysis reveals very long chain ceramides as validated biomarkers of Friedreich’s ataxia

12. A non-synonymous single nucleotide polymorphism in SIRT6 predicts neurological severity in Friedreich ataxia

13. SARS-CoV-2 in patients with Friedreich ataxia

14. Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

15. Direct utility of natural history data in analysis of clinical trials: Propensity match-based analysis of Omaveloxolone in Friedreich ataxia using the FA-COMS dataset

17. Frataxin deficiency lowers lean mass and triggers the integrated stress response in skeletal muscle

18. DNA methylation in Friedreich ataxia silences expression of frataxin isoform E

19. Clinical Evidence for Variegated Silencing in Patients With Friedreich Ataxia

20. Frataxin controls ketone body metabolism through regulation of OXCT1

21. Cerebellar Pathology in an Inducible Mouse Model of Friedreich Ataxia

22. Bone Mineral Density and Current Bone Health Screening Practices in Friedreich's Ataxia

23. DNA methylation in Friedreich ataxia silences expression of frataxin isoform E

24. Natural History of Friedreich's Ataxia: Heterogeneity of Neurological Progression and Consequences for Clinical Trial Design

25. Epigenetic Heterogeneity in Friedreich Ataxia Underlies Variable FXN Reactivation

26. FXNgene methylation determines carrier status in Friedreich ataxia

27. Skin fibroblast metabolomic profiling reveals that lipid dysfunction predicts the severity of Friedreich’s ataxia

28. The Role of Serum Levels of Neurofilament Light (NfL) Chain as a Biomarker in Friedreich Ataxia

29. Friedreich’s Ataxia related Diabetes: Epidemiology and management practices

30. Randomized, double-blind, placebo-controlled study of interferon

31. Identification of a novel missense mutation in Friedreich's ataxia -FXN

32. Anti-NMDA Receptor Encephalitis: Clinical Features and Basic Mechanisms

33. Effects of genetic severity on glucose homeostasis in Friedreich ataxia

34. D-Serine and Serine Racemase Are Associated with PSD-95 and Glutamatergic Synapse Stability

36. Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia

37. Attributes of highly effective criminal defense negotiators

39. Perceived Judicial Hostility to Criminal Trials

40. The Nature of Occupational Stress Among Public Defenders

42. Common data elements for clinical research in Friedreich's ataxia

43. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial

44. NMDA receptor modulation by the neuropeptide apelin: implications for excitotoxic injury

45. Clinical measures of dysarthria in Friedreich Ataxia

47. Apelin, an endogenous neuronal peptide, protects hippocampal neurons against excitotoxic injury

48. Neurogenetics

49. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation

50. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro

Catalog

Books, media, physical & digital resources